No abstract

Dr Lambin is inventor of two patents on radiomics and one non patentable invention (software), licensed to Oncoradiomics and has (minority) shares in the company Oncoradiomics. Dr.

Single vocal cord irradiation with IMRT resulted in good target coverage and provided significant sparing of the critical structures. This has the potential to improve the quality-of-life outcomes after RT and maintain the same local control rates.

Inhibition of ATR with AZD6738 in combination with radiotherapy increases tumour growth delay without observable augmentation of late radiation induced toxicity further underpinning translation towards clinical evaluation in NSCLC.